Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences is well-positioned to continue its rapid progression towards key clinical milestones, as evidenced by the recently reported enrollment of over 85% in its PRECISE-AD study for its Alzheimer's candidate, PMN310. With two pivotal data readouts expected in 2026 - interim data in 2Q26 and top-line data in 4Q26 - ProMIS is on track to provide early validation of its differentiated therapeutic approach, targeting toxic amyloid-beta oligomers while intentionally avoiding plaque, to address neurodegeneration without the safety concerns associated with current therapies. This progress, coupled with a favorable safety profile and a strong balance sheet with ~$15M in cash, makes ProMIS a promising investment opportunity.

Bears say

ProMIS Neurosciences is a clinical-stage biotechnology company with a promising lead anti-amyloid candidate, PMN310, currently in Phase 1b trials for Alzheimer's disease. However, the company's current financials do not show any product revenue, and there are potential risks, including failure to show efficacy or unexpected safety issues. Additionally, the company may need to raise money in the markets until they become cash flow positive. Therefore, the analyst maintains a negative outlook on the stock.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.